Neurol. praxi. 2019;20(2):115-120 | DOI: 10.36290/neu.2019.013

Chronic migraine

MUDr. Tomáš Nežádal, Ph.D.
Neurologické oddělení Ústřední vojenské nemocnice, Institut neuropsychiatrické péče, 1. LF UK, Praha

Chronic migraine is a very frequent neurological disease, which prevalence in the population and health restrictions rank third
after cerebrovascular events and just below dementia. According to the latest International Classification of Headaches (ICHD-3) is
classified as a separate migraine subtype and is defined as at least 15 days with a headache in the month, of which 8 or more are
migraine-like. The disease is often drug-resistant and accompanied by therapeutic nihilism. Currently, however, proper diagnosis
can lead to new treatment options such as CGRP antibodies or neurostimulation methods.

Keywords: chronic migraine, preventive treatment, CGRP monoclonal antibodies, neurostimulation

Received: February 11, 2019; Accepted: February 11, 2019; Published: April 23, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Nežádal T. Chronic migraine. Neurol. praxi. 2019;20(2):115-120. doi: 10.36290/neu.2019.013.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Adams AM, Serrano D, Buse DC, Reed ML, Marske V, Fanning KM, Lipton RB. The impact of chronic migraine: the chronic migraine epidemiology and outcomes (CaMEO) Study methods and baseline results. Cephalalgia 2015; 35: 563-578. Go to original source... Go to PubMed...
    2. American Headache Society. The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice. Headache 2019; 59(1): 1-18. Go to original source...
    3. Barbanti P, Grazzi L, Egeo G, Padovan AM, Liebler E, Bussone G. Non-invasive vagus nerve stimulation for acute treatment of high-frequency and chronic migraine: an open-label study. J Headache Pain. 2015; 16: 61. Go to original source...
    4. Blumenfeld AM, Stark RJ, Freeman MC, Orejudos A, Manack Adams A. Long term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. J Headache Pain 2018; 19(1): 13. Go to original source...
    5. Buse DC, Manack A, Serrano D, Turkel C, Lipton RB. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry 2010; 81: 428-433. Go to original source...
    6. de Goffau MJ, Klaver ARE, Willemsen MG, Bindels PJE, Verhagen AP. The Effectiveness of Treatments for Patients With Medication Overuse Headache: A Systematic Review and Meta-Analysis. J Pain. 2017; 18(6): 615-627. Go to original source...
    7. Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, Silberstein SD, Brin MF; PREEMPT 2 Chronic Migraine Study Group. Onabotulinumtoxin A for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010; 30: 804-814. Go to original source... Go to PubMed...
    8. Diener H, Dodick D, Goadsby P, Lipton RB, Olesen J, Silberstein S. Chronic migraine - classification, characteristics, and treatment. Nat Rev Neurol 2012; 14: 162-171. Go to original source...
    9. Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial. JAMA 2018; 319: 1999-2008. Go to original source... Go to PubMed...
    10. Duncan C, Carod Artal FJ, Coulson A; Scottish Intercollegiate Guidelines Network. Publication 155. Pharmacological management of migraine. A national clinical guideline. Edinburg: SIGN; February 2018.
    11. Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, Sándor PS; European Federation of Neurological Societies; EFNS guideline on the drug treatment of migraine-revised report of an EFNS task force. Eur J Neurol 2009; 16(9): 968-981. Go to original source...
    12. Gawel, MJ, Rothbart PJ. Occipital nerve block in the management of headache and cervical pain. Cephalalgia 1992; 12: 9-13. Go to original source... Go to PubMed...
    13. Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, Sapra S, Picard H, Mikol DD, Lenz RA. A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med 2017; 377: 2123-2132. Go to original source...
    14. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018; 38(1) 1-211. Go to original source...
    15. Chu LF, Angst MS, Clark D. Opioid-induced hyperalgesia in humans: Molecular mechanisms and clinical considerations. Clin J Pain 2008; 24: 479-496. Go to original source...
    16. Lipton RB. Burden of Everyday Activities and Physical Impairment by Migraine Phase. 60th Annual Scientific Meeting American Headache Society 2018; Poster PF120LB.
    17. Mathew NT. Pathophysiology of Chronic Migraine and Mode of Action of Preventive Medications. Headache 2011; 51; S2: 84-92. Go to original source... Go to PubMed...
    18. Natoli JL, Manack A, Dean B, Butler Q, Turkel CC, Stovner L, Lipton RB. Global prevalence of chronic migraine: a systematic review. Cephalalgia 2010; 30: 599-609. Go to original source... Go to PubMed...
    19. Schoenen J, Vandersmissen B, Jeangette S, Herroelen L, Vandenheede M, Gepard P, Magis D. Prevention of migraine by supraorbital transcutaneous neurostimulation using the Cefaly(R) device (PREMICE): a multi-centre, randomized, sham-controlled trial. J Headache Pain 2013; 14(Suppl. 1): 184. Go to original source...
    20. Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E; Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012; 78(17): 1337-1345. Go to original source... Go to PubMed...
    21. Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia 2018; 38: 1442-1454. Go to original source... Go to PubMed...
    22. Starling AJ, Tepper SJ, Marmura MJ, Shamim EA, Robbins MS, Hindiyeh N, Charles AC, Goadsby PJ, Lipton RB, Silberstein SD, Gelfand AA, Chiacchierini RP, Dodick DW. A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study). Cephalalgia 2018; 38: 1038-1048. Go to original source... Go to PubMed...
    23. Steiner TJ, Stovner LJ, Vos T. GBD 2015: migraine is the third cause of disability in under 50s. J Headache Pain 2016; 17(1): 104. Go to original source...
    24. Tepper S, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein S, Winner P, Leonardi D, Mikol D, Lenz R. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 2017; 16: 425-434. Go to original source...
    25. Vandenbussche N, Laterza D, Lisicki M, Lloyd J, Lupi C, Tischler H, Toom K7, Vandervorst F, Quintana S, Paemeleire K, Katsarava Z. Medication-overuse headache: a widely recognized entity amidst ongoing debate. J Headache Pain 2018; 19(1): 50 (1-14). Go to original source...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.